Download Briefing Note: Short Review about NNRTI & Rifampin Interactions

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Antiretroviral Treatment in the
Context of TB/HIV Co-infection
Major Aspects of Background Document 2
Marco Vitoria
HIV/AIDS Department
WHO Geneva
Feb 2005
ART for HIV+ with TB
• Possible Strategies currently recommended:
– Delay ART (and treat TB with RMP based
regimens)
– Use any ART regimen + anti-TB regimens
without RMP
– Use a RMP-compatible ART regimen
• 2 NRTI + NNRTI (EFV or NVP) -1st line
• 2 NRTI + PI/r (SQV/r or LPV/r + RTV) -2nd line
• 3 NRTI ( with ABC) – Alternative 1st line
Important Concepts to be consider
in TB/HIV treatemnt
• Rifampin and CYP 450 (3A4, 2B6, 3A5)
• CYP and Host Genetics("Farmacogenomics")
• ART pK and Safety (hepatic) in patients with
TB/HIV co-infection under dual treatment
(ART & RMP)
Objectives
• Review of the Literature (Pub Med)
• Overview of concomitant use of NNRTI and PI with
antituberculous drugs (emphasis in safety and efficacy of
NNRTI and PI when used concomitantly with RMP)
• What we need to know ?
• List of major ongoing & planned studies on ART in
TB/HIV patients
• What to do in the meantime?
Major Questions
• Nevirapine versus Efavirenz
– Efficacy in TB/HIV
• Nevirapine and Rifampin
– Resistance & Efficacy (pK interactions)
– Toxicity Risk
• Efavirenz and Rifampin
– Safest Dose (efficacy vs adverse effects)
• PI and Rifampin
– Efficacy and safety (hepatic)
NVP vs EFV: What is the better
drug in HIV Treatment ?
Current WHO Guidelines
• NVP: 1st line regimens in RPS, available as FDC
(adherence, cost, operational aspects). Good
tolerance, favourable lipid profile (reducing
coronary risk). Led in dose. Hepatotoxicity and
Rash.
• EFV: 1st line regimen - Preferential drug in
TB/HIV, contraindicated in pregnancy and
psychiatric disorders. Once daily drug . CNS
symptoms, hypercolesterolemia and
ginecomastia.
NVP vs EFV: What is the better
drug in HIV Treatment ?
• Metanalysis: Equivalent virologic
suppression and short term efficacy at 24
and 48 weeks
• One non controlled study showed limited
virologic and immunologic advantage of
EFV in the first 12 months, but no relevant
efficacy difference throughout 18 months
comparison
NVP vs EFV: What is the better
drug in HIV Treatment ?
• Pharmacokinetics: NVP and EFV partially
metabolized by CYP 3A4 and CYP 2B6
and mild inducers of this enzyme system
• RMP pK don't change significantly.
• Small pK studies show large interpatient
variability
NVP vs EFV: What is the better
drug in HIV Treatment ?
• Different side effect profile:
– Hypersensitivity syndrome & skin rash
• NVP (7%) versus EFV (4%)
– Hepatitis
• NVP (2%) versus EFV (0,3%)
– CNS Symptoms
• EFV (40-50% in the first weeks of treatment. Suicidal attempting
1-3%)
• Clinical Practice: Drugs are equivalent options:
choice should be based on safety profile and
specific contraindications
NVP and RMP: Concerns about
Resistance, Efficacy and Toxicity
• Drug Interaction and NVP Resistance/Faliure:
– NVP: High Therapeutic Index
– Reduction of NVP serum levels (31-58%) but generally
above the viral inhibitory concentration
– Good immunological and virological response in small
studies (non controlled)
– No dose adjustment recommended by majority of
experts
– Large intervariability independently of RMP
concomitant use (further investigation required)
Rifampin – NVP case serie from
HIVNAT pK Lab (n=60)
Nevirapine + Rifampicin
16
NVP conc.
14
12
10
8
6
4
2
0
0
3
6
9
12
15
Time (h)
85% of NVP levels in therapeutic range
David Burger; 2005 BKK Symp HIV Med, data provided by Saskia Autar
NVP and RMP: Concerns about Resistance,
Efficacy and Toxicity
General NVP Toxicity Profile
• Concern about RMP-NVP use (lack of solid data about concomitant use)
• Mechanisms: Direct and immune mediated hepatic & skin involvement
– Stratified & comparative risk of any hepatic reaction with NVP use in HIV+
patients (studies without TB):
• NVP versus other ARV (10x)
• NVP in with CD4 > 400/mm3 (3x)
• NVP in  with CD4 > 250/mm3 (12x)
– Presence of liver disease
•
•
•
•
•
HBV and HCV co-infection
Histological stage and fibrosis
pK of NNRTI not significantly modified
NVP accelerating hepatic fibrosis ?
No data on additive risk of hepatotoxicity of TB drugs in HIV-HBV or HIV-HCV coinfection
– Elevated plasma levels (hepatic disease or slower clearance- CYP2B6)
– NVP plasma levels > 6 mg/l (92% of liver toxicity)
– NVP levels > 5.3 mg/l in 1st 90 days (2.5 x for rash)
– However other studies (observational cohorts) didn't find any correlation
NVP and RMP: Concerns about Resistance,
Efficacy and Toxicity
NVP Toxicity Profile (cont'd)
• Increase in liver enzymes are common but generally
asymptomatic and in low/moderate grade (small and non
controlled studies).
• Analysis of Clinical Trials with NVP (17 studies)
– 10% of NVP treated patients with elevated ALT (> 5x), but more
than 2/3 asymptomatic (almost half of symptomatic with
concomitant rash).
• Analysis of Observational Studies: NVP use not associated
with significant increase in the risk of severe clinical
hepatic events when compared with other ARV drugs.
• Small non controlled studies shown increase in ALT and
clinical hepatitis when NVP used with RMP
• WHO recommendation: NVP and RMP should be use with
caution only no alternative available and with close
monitoring
EFV dose in TB/HIV co-infection
treated with RMP (600 versus 800 mg)
•
•
Similar pK phenomena observed with NVP and RMP interaction (reduction in
EFV levels:13-33%).
Safety profile:
– Apparently is dose related
– CNS adverse effects are frequent in the beginning of treatment (50%) but
transitory (5-10% after 3 months).
– Neuropsychiatry symptoms after 3 months in 25% of patients.
– Sleep abnormalities associated with higher plasma levels (>4 mg/l).
•
•
Small non controlled studies shown effective, pharmacological, clinical,
immunological and virologic response with conventional 600 mg EFV dose
pK studies accordingly body weight: EFV plasma concentration patients
using RMP:
–
Patients with less than 50-60 Kg: similar to patients without TB (600 mg is
adequate)
– More than 50-60 kg : need better evaluation (small study shown EFV
concentrations 50% lower)
•
•
Large interpatient variability in small pK studies
Clearance of EFV was higher in Caucasians than in Afro-Americans and
Hispanics (impact on safety profile)
EFV and Rifampin: TDM and Efficacy Study
Plasma EFV (C12) levels of EFV 600 vs. 800 mg group
mg/L
25
TDM at Week 2 after treatment
EFV 800
20
n = 40
15
10
EFV 600
92% of patients with
therapeutic levels
n = 38
8% < 1mg/L
5
Appropriate EFV level 1-4
3.02
0% < 1mg/L
3.39
0
Weerawat Manosuthi et al. Bangkok AIDS Conf .2004
(TDM done at HIVNAT; study Supported by HSRI, Thailand); D. Burger, 2005 BKK Symp HIV Med
Protease Inhibitors and Rifampin:
Safety and Clinical Efficacy
• Impact of RMP on PI levels: 80-90% reduction
• "Pharmacoenhancement" with low dose RTV can overcome RMP
induction effect of some PIs:
– SQV/r (1000/100 BID, 400/400 BID, 1600/200 MID)
– LPV/r + RTV (400/100 + 300 BID)
•
•
Pharmacological booster increase the side effect risk and can compromise
adherence
- Major side effect associated with boosted PIs: Hepatotoxicity
– HBV & HCV co-infection associated with higher risk of elevation of liver
enzymes (higher rates of grade 3 / 4 ALT elevations)
– Comparative studies: No difference in ARV discontinuation, other hepatic events
or death when compared without HBV & HCV co-infection
– pK of PIs can be altered by hepatic disease but no change in doses are
recommended for SQV/r and LPV/RTV (limited data)
– Large majority of patients treated without side effects (low dose RTV didn't affect
hepatic safety profile of PI based therapy)
Protease Inhibitors and Rifampin:
Safety and Clinical Efficacy
• Retrospective and comparative study in patients using
RMP - 3 NRTI, 2NRTI/NNRTI and 2NRTI/SQVr: well
tolerated and safe but data is limited
• TB/HIV using RMP and SQV/r:
– SQV/r 1600/200 (SQV AUC reduced by50% but still
under therapeutic concentrations and clincial efficacy
mantained)
– SQV/r 1000/100 in HIV+: clinical efficacy and safety ,
but small Phase I study in HIV negative patients
shown high rate of clinical hepatitis (AE less
pronounced in HIV+?)
– SQV/r 400/400, and LPV/RTV 400/400 – Apparently
effective and safe but even more limited data
Conclusion: More studies are
needed…
•
•
•
•
Few published data (safety profile)
Limited number of patients
No controlled studies
Mixed and conflicting results
What We Need to Know?
• ART & RMP: Studies on safety, efficacy,
pK evaluation and pharmacovigilance
(better define ART strategy in TB/HIV)
• Review the role of Triple Nukes in TB/HIV
co-infection (DART Trial)
• Ongoing and planned studies on ART for
HIV-infected TB patients (see database)
What to Do in the Mean Time?
• Need more clear recommendations and best
informed practice in ART management of TB/HIV
• Better inform HCW about potential risks and
benefits of ART & RMP and mixed/conflicting
results in scientific literature
• EFV - Preferential drug (no dose adjustment for
patients with less 50-60 kg)
• PI/r & NVP in patients using RMP– Use with
caution
• Establish the potential role of some triple nukes
regimens in TB/HIV treatment
Related documents